Literature DB >> 22397815

The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy.

Bato Lazarevic1, Clara Hammarström, Jin Yang, Hakon Ramberg, Lien M Diep, Steinar J Karlsen, Omer Kucuk, Fahri Saatcioglu, Kristin A Taskèn, Aud Svindland.   

Abstract

Nutritionally relevant levels of genistein, the predominant isoflavone in soyabean associated with lower risk of prostate cancer (PCa), may modulate the expression of prostate tissue biomarkers associated with cancer prediction and progression. A phase 2 placebo-controlled, randomised, double-blind clinical trial was conducted in forty-seven Norwegian patients before prostatectomy. Intervention was 30 mg genistein or placebo capsules daily for 3-6 weeks. Luminal cells from malignant and benign glands were isolated with laser capture microdissection and the mRNA levels of androgen-related biomarkers (androgen receptor, NK3 homeobox 1, kallikrein-related peptide 4 (KLK4)) and cell cycle-related genes (p21 Waf1/Cip1 , p27 Kip1 , p53) were analysed with real-time semiquantitative PCR. Immunohistochemistry of androgen-, cell cycle-, proliferative- (Ki67 nuclear antigen), apoptotic- (B-cell CLL/lymphoma 2 (BCL-2) and BCL-2-associated X protein) and neuroendocrine differentiation-related biomarkers (neuron-specific enolase and cytoplasmic chromogranin A) was performed using tissue microarrays containing normal, Gleason grade 3 and grade 4 prostate tissues. There were no significant effects by genistein intervention on proliferation-, cell cycle-, apoptosis- or neuroendocrine biomarkers. Genistein intervention, however, significantly reduced the mRNA level of KLK4 in tumour cells (P = 0·033) and there was a non-significant reduction in androgen and cell cycle-related biomarkers, except for p27Kip1, whose expression in the nuclear compartment was increased. Genistein intervention modulated the expression of several biomarkers which may be related to PCa prediction and progression. The present study supports genistein as a chemopreventive agent in PCa. Further investigation is warranted in larger and longer-duration studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22397815     DOI: 10.1017/S0007114512000384

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  18 in total

1.  Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells.

Authors:  Shumin Zhang; Yanru Wang; Zhengjia Chen; Sungjin Kim; Shareen Iqbal; Andrew Chi; Chad Ritenour; Yongqiang A Wang; Omer Kucuk; Daqing Wu
Journal:  Prostate       Date:  2013-09-02       Impact factor: 4.104

2.  Effects of estrogen and estrus cycle on pharmacokinetics, absorption, and disposition of genistein in female Sprague-Dawley rats.

Authors:  Kaustubh H Kulkarni; Zhen Yang; Tao Niu; Ming Hu
Journal:  J Agric Food Chem       Date:  2012-08-03       Impact factor: 5.279

Review 3.  Future directions in the prevention of prostate cancer.

Authors:  Ian M Thompson; April B Cabang; Michael J Wargovich
Journal:  Nat Rev Clin Oncol       Date:  2013-11-26       Impact factor: 66.675

Review 4.  Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges.

Authors:  Eswar Shankar; Rajnee Kanwal; Mario Candamo; Sanjay Gupta
Journal:  Semin Cancer Biol       Date:  2016-04-23       Impact factor: 15.707

Review 5.  Current Perspectives on the Beneficial Effects of Soybean Isoflavones and Their Metabolites for Humans.

Authors:  Il-Sup Kim
Journal:  Antioxidants (Basel)       Date:  2021-06-30

Review 6.  Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications.

Authors:  Gagan Chhabra; Chandra K Singh; Mary Ann Ndiaye; Samantha Fedorowicz; Arielle Molot; Nihal Ahmad
Journal:  Cancer Lett       Date:  2018-02-20       Impact factor: 8.679

Review 7.  A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality.

Authors:  Lucy E Hackshaw-McGeagh; Rachel E Perry; Verity A Leach; Sara Qandil; Mona Jeffreys; Richard M Martin; J Athene Lane
Journal:  Cancer Causes Control       Date:  2015-09-09       Impact factor: 2.506

Review 8.  Nutrition, dietary interventions and prostate cancer: the latest evidence.

Authors:  Pao-Hwa Lin; William Aronson; Stephen J Freedland
Journal:  BMC Med       Date:  2015-01-08       Impact factor: 8.775

Review 9.  Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits.

Authors:  Javad Sharifi-Rad; Cristina Quispe; Muhammad Imran; Abdur Rauf; Muhammad Nadeem; Tanweer Aslam Gondal; Bashir Ahmad; Muhammad Atif; Mohammad S Mubarak; Oksana Sytar; Oxana Mihailovna Zhilina; Ekaterina Robertovna Garsiya; Antonella Smeriglio; Domenico Trombetta; Daniel Gabriel Pons; Miquel Martorell; Susana M Cardoso; Ahmad Faizal Abdull Razis; Usman Sunusi; Ramla Muhammad Kamal; Lia Sanda Rotariu; Monica Butnariu; Anca Oana Docea; Daniela Calina
Journal:  Oxid Med Cell Longev       Date:  2021-07-19       Impact factor: 6.543

Review 10.  Inducers of Senescence, Toxic Compounds, and Senolytics: The Multiple Faces of Nrf2-Activating Phytochemicals in Cancer Adjuvant Therapy.

Authors:  Marco Malavolta; Massimo Bracci; Lory Santarelli; Md Abu Sayeed; Elisa Pierpaoli; Robertina Giacconi; Laura Costarelli; Francesco Piacenza; Andrea Basso; Maurizio Cardelli; Mauro Provinciali
Journal:  Mediators Inflamm       Date:  2018-02-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.